All posts by: Michael Zand

GSK wins US shingles vaccine approval, UK nod for gene therapy
Reuters
It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease — a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene …
GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in USProactive Investors UK

all 14 news articles »

GSK wins US shingles vaccine approval, UK nod for gene therapy
Reuters
It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease — a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene …
GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in USProactive Investors UK

all 52 news articles »

GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in US
Proactive Investors UK
Britain’s National Institute for Health and Care Excellence (NICE) said in draft guidance that the Strimvelis gene therapy improves overall survival in patients with adenosine deaminase deficiency, or ADA-SCID, compared with standard stem cell …

and more »

The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV
Labiotech.eu (blog)
Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and …

Britain Backs GSK’s Gene Therapy for ‘Bubble Boy’ Syndrome
New York Times
Britain’s National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem …

Britain backs GSK’s gene therapy for ‘bubble boy’ syndrome
Reuters
Britain’s National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem …
NHS to fund gene therapy for ‘bubble babies’ – The TelegraphTelegraph.co.uk
NICE approves gene therapy for rare ‘bubble baby syndrome’NICE
NICE nod for GSK’s ‘bubble baby syndrome’ gene therapyPharmaTimes
The Times
all 8 news articles »

NHS to fund gene therapy for ‘bubble babies’
Telegraph.co.uk
THE NHS will fund gene therapy for the first time, with a £500,000 treatment for “bubble baby syndrome”. Three babies are born each year with an immune defiency condition which leave them at constant risk of developing life-threatening infections.